This research project aims to integrate microbiome-based technologies as innovative therapeutic solutions for respiratory fungal infections, with a particular focus on aspergillosis. Unlike research on the gut microbiota, studies on the respiratory microbiota are still in their early stages. This project seeks to evaluate the potential of Live Biotherapeutic Products (LBPs) adapted to the respiratory tract environment. These LBPs are derived from bacteria isolated from the human respiratory tract and are evaluated for their efficacy and safety in preclinical models. The ultimate goal is to develop a prototype LBP with a defined composition and health claims, paving the way for future clinical trials.